Celltrion Invests In UK’s Iksuda
Takes Controlling Stake In ADC Specialist Through $47m Financing Round
Celltrion has taken a controlling stake in ADC specialist Iksuda as part of a $47m financing round that has just been closed by the UK-based company.
You may also be interested in...
Celltrion has bought a portfolio of selected products in the Asia-Pacific region from Takeda, marking a foray into small-molecule drugs.
The FDA’s acceptance of Amneal’s filing for bevacizumab brings the company a step closer to its goal of launching a US biosimilar every year to 2023.
As part of a “structured dialog” initiated with pharmaceutical industry stakeholders by the European Commission, local off-patent industry association Medicines for Europe has set out the key reforms needed to bolster the sector.